Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ARGX, LLY, RYTM, MDGL, RVMD, and represent 22.42% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CDTX (+$11M), Heartflow Inc/Sh (+$8.4M), LENZ (+$7.1M), TVTX (+$6.1M), MBX, BBIO, OCUL, ALKS, MLYS, DYN.
- Started 9 new stock positions in OCUL, EYPT, MRSN, BBIO, CNTA, ALKS, MLTX, MBX, Heartflow Inc/Sh.
- Reduced shares in these 10 stocks: MRUS (-$44M), ARGX (-$24M), BPMC (-$24M), INSM (-$20M), , OSCR (-$15M), RYTM (-$15M), ACHC (-$13M), ALNY (-$12M), WST (-$11M).
- Sold out of its positions in ADAP, BPMC, CGEM, ETNB, Mersana Therapeutics, NUVL, OSCR, LUNG, SRPT, UNH.
- Rock Springs Capital Management was a net seller of stock by $-196M.
- Rock Springs Capital Management has $1.7B in assets under management (AUM), dropping by 6.65%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 92 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Argenx Se Sponsored Adr (ARGX) | 6.2 | $105M | -18% | 143k | 737.56 |
|
| Eli Lilly & Co. (LLY) | 4.7 | $80M | -9% | 105k | 763.00 |
|
| Rhythm Pharmaceuticals (RYTM) | 4.2 | $72M | -16% | 717k | 100.99 |
|
| Madrigal Pharmaceuticals (MDGL) | 3.7 | $63M | 138k | 458.66 |
|
|
| Revolution Medicines (RVMD) | 3.6 | $62M | 1.3M | 46.70 |
|
|
| Merus N V (MRUS) | 3.3 | $56M | -43% | 597k | 94.15 |
|
| Mirum Pharmaceuticals (MIRM) | 3.3 | $56M | -6% | 761k | 73.31 |
|
| Insmed Com Par $.01 (INSM) | 3.2 | $55M | -26% | 385k | 144.01 |
|
| Travere Therapeutics (TVTX) | 3.0 | $52M | +13% | 2.2M | 23.90 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.5 | $43M | 215k | 198.81 |
|
|
| Irhythm Technologies (IRTC) | 2.4 | $40M | -3% | 235k | 171.99 |
|
| Agios Pharmaceuticals (AGIO) | 2.2 | $39M | -3% | 959k | 40.14 |
|
| Ultragenyx Pharmaceutical (RARE) | 2.2 | $38M | -10% | 1.2M | 30.08 |
|
| Intuitive Surgical Com New (ISRG) | 2.1 | $37M | 82k | 447.23 |
|
|
| Boston Scientific Corporation (BSX) | 2.1 | $35M | 360k | 97.63 |
|
|
| Xenon Pharmaceuticals (XENE) | 2.0 | $34M | -8% | 852k | 40.15 |
|
| Alnylam Pharmaceuticals (ALNY) | 2.0 | $34M | -25% | 74k | 456.00 |
|
| EXACT Sciences Corporation (EXAS) | 1.9 | $33M | +3% | 594k | 54.71 |
|
| Penumbra (PEN) | 1.8 | $31M | -6% | 121k | 253.32 |
|
| Akero Therapeutics (AKRO) | 1.7 | $30M | -2% | 627k | 47.48 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.7 | $30M | 794k | 37.24 |
|
|
| Zai Lab Adr (ZLAB) | 1.6 | $27M | -9% | 791k | 33.89 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.6 | $27M | -16% | 951k | 28.00 |
|
| Kymera Therapeutics (KYMR) | 1.5 | $26M | 450k | 56.60 |
|
|
| Tenet Healthcare Corp Com New (THC) | 1.5 | $25M | -3% | 125k | 203.04 |
|
| Evolent Health Cl A (EVH) | 1.5 | $25M | +4% | 3.0M | 8.46 |
|
| Caris Life Sciences (CAI) | 1.4 | $24M | 794k | 30.25 |
|
|
| Cidara Therapeutics Com New (CDTX) | 1.4 | $24M | +85% | 249k | 95.76 |
|
| Dex (DXCM) | 1.2 | $21M | +10% | 317k | 67.29 |
|
| Omada Health (OMDA) | 1.2 | $20M | 920k | 22.11 |
|
|
| Celldex Therapeutics Com New (CLDX) | 1.1 | $19M | -11% | 722k | 25.87 |
|
| Vera Therapeutics Cl A (VERA) | 1.0 | $18M | 617k | 29.06 |
|
|
| Newamsterdam Pharma Company Ordinary Shares Call Option (NAMS) | 1.0 | $18M | +17% | 628k | 28.44 |
|
| Phreesia (PHR) | 1.0 | $18M | -10% | 749k | 23.52 |
|
| Tarsus Pharmaceuticals (TARS) | 1.0 | $17M | -22% | 288k | 59.43 |
|
| Compass Therapeutics (CMPX) | 0.9 | $16M | -9% | 4.5M | 3.50 |
|
| Pharvaris N V (PHVS) | 0.9 | $16M | 623k | 24.95 |
|
|
| Brooks Automation (AZTA) | 0.9 | $16M | 540k | 28.72 |
|
|
| Mineralys Therapeutics (MLYS) | 0.9 | $16M | +25% | 408k | 37.92 |
|
| Amicus Therapeutics (FOLD) | 0.9 | $15M | 1.9M | 7.88 |
|
|
| Spdr Series Trust S&p Biotech (XBI) | 0.9 | $15M | 152k | 100.20 |
|
|
| Arcellx Common Stock (ACLX) | 0.9 | $15M | -3% | 179k | 82.10 |
|
| Summit Therapeutics (SMMT) | 0.9 | $15M | 710k | 20.66 |
|
|
| Cogent Biosciences (COGT) | 0.8 | $15M | +26% | 1.0M | 14.36 |
|
| Enliven Therapeutics (ELVN) | 0.8 | $14M | -2% | 686k | 20.47 |
|
| Zenas Biopharma (ZBIO) | 0.8 | $13M | -9% | 581k | 22.20 |
|
| Neurocrine Biosciences (NBIX) | 0.7 | $13M | 90k | 140.38 |
|
|
| Ardelyx (ARDX) | 0.7 | $13M | 2.3M | 5.51 |
|
|
| Danaher Corporation (DHR) | 0.7 | $12M | +4% | 62k | 198.26 |
|
| Lenz Therapeutics (LENZ) | 0.6 | $11M | +181% | 236k | 46.58 |
|
| Soleno Therapeutics (SLNO) | 0.6 | $10M | 155k | 67.60 |
|
|
| Dyne Therapeutics (DYN) | 0.6 | $10M | +41% | 824k | 12.65 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.6 | $9.4M | +2% | 4.6M | 2.06 |
|
| Aclaris Therapeutics (ACRS) | 0.5 | $8.8M | -3% | 4.6M | 1.90 |
|
| Gossamer Bio (GOSS) | 0.5 | $8.6M | 3.3M | 2.63 |
|
|
| Heartflow Inc/Sh | 0.5 | $8.4M | NEW | 250k | 33.66 |
|
| Inspire Med Sys (INSP) | 0.5 | $8.2M | +2% | 111k | 74.20 |
|
| Agilon Health (AGL) | 0.4 | $7.2M | +6% | 7.0M | 1.03 |
|
| Edwards Lifesciences (EW) | 0.4 | $6.8M | -32% | 88k | 77.77 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.4 | $6.8M | 500k | 13.59 |
|
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.4 | $6.7M | 9.6M | 0.70 |
|
|
| Regeneron Pharmaceuticals (REGN) | 0.4 | $6.4M | 11k | 562.27 |
|
|
| Bicara Therapeutics (BCAX) | 0.3 | $5.9M | +10% | 371k | 15.79 |
|
| Janux Therapeutics (JANX) | 0.3 | $5.1M | 210k | 24.44 |
|
|
| Mbx Biosciences (MBX) | 0.3 | $4.9M | NEW | 283k | 17.50 |
|
| Thermo Fisher Scientific (TMO) | 0.3 | $4.9M | 10k | 485.02 |
|
|
| Bridgebio Pharma (BBIO) | 0.3 | $4.4M | NEW | 85k | 51.94 |
|
| Alphatec Hldgs Com New (ATEC) | 0.3 | $4.4M | +13% | 303k | 14.54 |
|
| Acadia Healthcare (ACHC) | 0.2 | $4.2M | -75% | 170k | 24.76 |
|
| Ocular Therapeutix (OCUL) | 0.2 | $3.5M | NEW | 300k | 11.69 |
|
| Talphera Com New (TLPH) | 0.2 | $3.2M | +1034% | 3.6M | 0.89 |
|
| Alkermes SHS (ALKS) | 0.2 | $3.2M | NEW | 107k | 30.00 |
|
| Sionna Therapeutics (SION) | 0.2 | $2.9M | 99k | 29.41 |
|
|
| Edap Tms S A Sponsored Adr (EDAP) | 0.2 | $2.9M | 1.3M | 2.29 |
|
|
| Jasper Therapeutics Com New (JSPR) | 0.2 | $2.6M | +101% | 1.1M | 2.38 |
|
| West Pharmaceutical Services (WST) | 0.1 | $2.6M | -80% | 9.8k | 262.33 |
|
| Apellis Pharmaceuticals (APLS) | 0.1 | $2.1M | +9% | 92k | 22.63 |
|
| Neurogene (NGNE) | 0.1 | $1.8M | 104k | 17.33 |
|
|
| Korro Bio (KRRO) | 0.1 | $1.7M | 36k | 47.89 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $1.7M | NEW | 69k | 24.25 |
|
| Perspective Therapeutics Com New (CATX) | 0.1 | $1.5M | 444k | 3.43 |
|
|
| Applied Therapeutics (APLT) | 0.1 | $1.3M | 2.1M | 0.60 |
|
|
| Mersana Therapeutics (MRSN) | 0.1 | $1.2M | NEW | 153k | 7.76 |
|
| Immunovant (IMVT) | 0.1 | $1.2M | -67% | 73k | 16.12 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.0 | $451k | NEW | 32k | 14.24 |
|
| Charles River Laboratories (CRL) | 0.0 | $422k | 2.7k | 156.46 |
|
|
| Vaxcyte (PCVX) | 0.0 | $400k | 11k | 36.02 |
|
|
| Novavax Com New (NVAX) | 0.0 | $390k | -16% | 45k | 8.67 |
|
| Prothena Corp SHS (PRTA) | 0.0 | $248k | -94% | 25k | 9.76 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.0 | $202k | NEW | 28k | 7.17 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $27k | 134k | 0.20 |
|
|
| Compugen Ord (CGEN) | 0.0 | $20k | -98% | 13k | 1.47 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2025 Q3 filed Nov. 14, 2025
- Rock Springs Capital Management 2025 Q2 filed Aug. 14, 2025
- Rock Springs Capital Management 2025 Q1 filed May 15, 2025
- Rock Springs Capital Management 2024 Q4 filed Feb. 14, 2025
- Rock Springs Capital Management 2024 Q3 filed Nov. 14, 2024
- Rock Springs Capital Management 2024 Q2 filed Aug. 14, 2024
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022
- Rock Springs Capital Management 2021 Q4 filed Feb. 14, 2022
- Rock Springs Capital Management 2021 Q3 filed Nov. 15, 2021